ACT for Osteoarthritis in India: What to Expect and Who Benefits | ALIV

Osteoarthritis (OA) — the degenerative joint disease affecting millions of Indian adults, most commonly in the knees, hips, and hands — represents one of the clearest clinical applications of ACT's regenerative paracrine mechanism. The chronic, low-grade synovial inflammation and progressive cartilage matrix degradation of OA are directly targetable by the anti-inflammatory and repair-signalling properties of an autologous cell preparation — making OA one of the conditions with the most mechanistically plausible and clinically observed responses to ACT at ALIV.

Why Conventional OA Treatment Eventually Plateaus

Conventional OA management — physiotherapy, NSAIDs, intra-articular corticosteroids, and eventually joint replacement — is effective through specific stages of the disease. Physiotherapy maintains function; NSAIDs manage inflammation symptomatically; corticosteroid injections provide temporary relief but, with repeated use, may actually accelerate cartilage degradation; and joint replacement is definitive but carries surgical risks and implant longevity limitations. Many patients — particularly those in their 50s and 60s who are too young for optimal implant longevity but too symptomatic for conservative management alone — find themselves at a frustrating therapeutic gap between adequate conservative care and surgical intervention. ACT is most clinically relevant in this gap.

The ACT Mechanism in Osteoarthritis

The ACT preparation introduces concentrated growth factors (PDGF, TGF-β, IGF-1) and mesenchymal stromal cell populations into the OA joint environment, which is characterised by elevated IL-1β and TNF-α driving chondrocyte death and matrix metalloproteinase (MMP) activity that degrades cartilage collagen. The growth factors and MSC paracrine signals: suppress IL-1β and TNF-α; reduce MMP activity and protect existing cartilage from further enzymatic degradation; stimulate chondrocyte activity and proteoglycan synthesis (cartilage matrix components); improve synovial fluid quality (lubricating properties); and promote subchondral bone remodelling that supports the overlying cartilage. The net effect is an anti-inflammatory, chondroprotective environment that, in responsive patients, produces meaningful improvements in pain, stiffness, and functional capacity. ALIV's OA ACT protocol is delivered as an intra-articular injection under ultrasound guidance at the target joint. See the full results timeline: ACT results — what to expect and when.

Who Responds Best to ACT for OA

The best ACT-OA candidates are patients with moderate osteoarthritis (Kellgren-Lawrence grade II or III on X-ray) who retain meaningful cartilage tissue to protect and support — there must be something left for the regenerative signals to work with. Early-stage OA (grade I) may respond very well but also responds to other less invasive approaches. End-stage OA (grade IV, bone-on-bone) has limited remaining cartilage and typically produces more modest ACT responses. Age is a factor — younger patients with better residual tissue health generally respond more robustly, though meaningful responses in patients in their 60s and 70s are well-documented at ALIV. NSAID cessation before and after the procedure significantly improves outcomes by allowing the inflammatory signalling that initiates and guides the repair response to proceed without pharmacological suppression.

Is ACT for OA an alternative to knee replacement?

ACT for OA is positioned as a disease-modifying and symptom-modifying intervention rather than a substitute for joint replacement in patients for whom replacement is the genuinely appropriate next step. For patients who are candidates for joint replacement but wish to defer it or explore regenerative options first, ACT offers a meaningful chance of extending the period of tolerable function without surgical intervention. For patients where joint replacement is strongly indicated and delayed access will compromise quality of life and function significantly, deferring replacement for ACT is not always the most clinically appropriate choice. This decision is made individually in consultation with the orthopaedic surgeon and ALIV's clinical team.

How many ACT sessions does a knee OA protocol involve?

Most OA protocols at ALIV involve a primary ACT administration followed by reassessment at three to six months. Where clinical response is good, a single course often provides benefit lasting twelve to eighteen months. In patients with moderate-severe OA and ongoing joint stress, a second session at twelve to eighteen months may be considered as a maintenance procedure. The protocol is individualised — some patients with bilateral knee OA may have both knees addressed in planned staged procedures.

Can I do physiotherapy alongside ACT for OA?

Yes — and ALIV strongly recommends it. Physiotherapy that strengthens the periarticular muscles (particularly quadriceps and hamstrings for knee OA) reduces the mechanical load on the joint cartilage and maximises the functional benefit of the anti-inflammatory and chondroprotective environment that ACT creates. The two are synergistic: ACT addresses the biological joint environment; physiotherapy optimises the mechanical loading context. Patients who combine both consistently produce better functional outcomes than those who receive ACT alone.